DE602006014139D1 - Sulfonamid-derivate als lebercarnitin-palmitoyl-transferase-hemmer - Google Patents

Sulfonamid-derivate als lebercarnitin-palmitoyl-transferase-hemmer

Info

Publication number
DE602006014139D1
DE602006014139D1 DE602006014139T DE602006014139T DE602006014139D1 DE 602006014139 D1 DE602006014139 D1 DE 602006014139D1 DE 602006014139 T DE602006014139 T DE 602006014139T DE 602006014139 T DE602006014139 T DE 602006014139T DE 602006014139 D1 DE602006014139 D1 DE 602006014139D1
Authority
DE
Germany
Prior art keywords
hemmer
lever
palmitoyl transferase
carnitine palmitoyl
sulphonamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014139T
Other languages
English (en)
Inventor
Konrad Bleicher
Simona Maria Ceccarelli
Odile Chomienne
Patrizio Mattei
Tanja Schulz-Gasch
Christoph Martin Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602006014139D1 publication Critical patent/DE602006014139D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006014139T 2005-06-06 2006-05-29 Sulfonamid-derivate als lebercarnitin-palmitoyl-transferase-hemmer Active DE602006014139D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05104904 2005-06-06
PCT/EP2006/062652 WO2006131452A1 (en) 2005-06-06 2006-05-29 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS

Publications (1)

Publication Number Publication Date
DE602006014139D1 true DE602006014139D1 (de) 2010-06-17

Family

ID=36940686

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014139T Active DE602006014139D1 (de) 2005-06-06 2006-05-29 Sulfonamid-derivate als lebercarnitin-palmitoyl-transferase-hemmer

Country Status (14)

Country Link
US (4) US7723538B2 (de)
EP (1) EP1891001B1 (de)
JP (1) JP4880678B2 (de)
KR (1) KR100956703B1 (de)
CN (1) CN101189210B (de)
AT (1) ATE466838T1 (de)
AU (1) AU2006256825B2 (de)
BR (1) BRPI0610877A2 (de)
CA (1) CA2608837C (de)
DE (1) DE602006014139D1 (de)
ES (1) ES2342842T3 (de)
IL (1) IL187409A (de)
MX (1) MX2007014927A (de)
WO (1) WO2006131452A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565245A (en) 2005-06-21 2010-07-30 Mitsui Chemicals Inc Amide derivative and pesticide containing such compound
AU2007214594B2 (en) 2006-02-13 2010-11-11 F. Hoffmann-La Roche Ag Heterobicyclic sulfonamide derivatives for the treatment of diabetes
US7799933B2 (en) * 2006-12-21 2010-09-21 Hoffman-La Roche Inc. Sulfonamide derivatives
KR100847448B1 (ko) * 2007-03-22 2008-07-21 한국화학연구원 3-아릴-5-알킬-1,2,4-옥사다이아졸 유도체, 그 제조방법 및이를 포함하는 비만 예방 또는 치료용 조성물
KR101140520B1 (ko) * 2007-06-01 2012-04-30 에프. 호프만-라 로슈 아게 피페리딘-아마이드 유도체
WO2009002433A1 (en) * 2007-06-22 2008-12-31 Dara Biosciences, Inc. Compositions and methods for treating skin disorders
JP2011525530A (ja) * 2008-06-24 2011-09-22 ダラ・バイオサイエンシズ，インコーポレイテッド 酵素阻害剤およびその使用
CN106890165A (zh) 2010-08-03 2017-06-27 奇斯药制品公司 包含磷酸二酯酶抑制剂的干粉制剂
RU2578975C2 (ru) 2010-08-03 2016-03-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
JP6347451B2 (ja) * 2013-08-02 2018-06-27 国立大学法人富山大学 （ベンゼンスルホニルアミノ）ベンズアミド誘導体およびそれらを有効成分とするｓｈｉｐ２阻害剤
CN104815154A (zh) * 2015-05-06 2015-08-05 山东宏济堂制药集团有限公司 一种清热润喉糖及其制备方法和应用
KR102606541B1 (ko) * 2021-04-23 2023-11-29 가천대학교 산학협력단 바이페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721130B2 (en) * 1996-06-28 2000-06-22 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2257937A1 (en) * 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
WO1999032433A1 (en) * 1997-12-23 1999-07-01 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
JP2001031652A (ja) * 1998-06-19 2001-02-06 Nissan Chem Ind Ltd 六員環複素環類
JP2004155788A (ja) * 1998-09-24 2004-06-03 Tanabe Seiyaku Co Ltd 腎疾患治療薬およびそのスクリーニング方法
JP2005523270A (ja) * 2002-02-08 2005-08-04 ジョーンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 体重を減少させる方法としてのｃｐｔ−１の促進
US20050113450A1 (en) * 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
US20090105218A1 (en) * 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use

Also Published As

Publication number Publication date
JP4880678B2 (ja) 2012-02-22
IL187409A0 (en) 2008-02-09
CA2608837A1 (en) 2006-12-14
US20100144762A1 (en) 2010-06-10
CN101189210A (zh) 2008-05-28
JP2008545770A (ja) 2008-12-18
IL187409A (en) 2012-03-29
EP1891001B1 (de) 2010-05-05
ES2342842T3 (es) 2010-07-15
EP1891001A1 (de) 2008-02-27
BRPI0610877A2 (pt) 2010-08-03
AU2006256825B2 (en) 2010-02-18
ATE466838T1 (de) 2010-05-15
AU2006256825A1 (en) 2006-12-14
WO2006131452A1 (en) 2006-12-14
US7723538B2 (en) 2010-05-25
US20120232104A1 (en) 2012-09-13
KR100956703B1 (ko) 2010-05-06
CA2608837C (en) 2011-08-02
KR20080008401A (ko) 2008-01-23
US20110319438A1 (en) 2011-12-29
CN101189210B (zh) 2012-06-06
US20060276494A1 (en) 2006-12-07
MX2007014927A (es) 2008-02-15

Similar Documents

Publication Publication Date Title
DE602006014139D1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl-transferase-hemmer
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
TW200745032A (en) Novel heterobicyclic derivatives
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
TW200800970A (en) Novel cycloalkane carboxamides
DE602005023015D1 (de) Indolderivate als viruzide
NO20075158L (no) Nye sykliske aminer
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
ECSP088082A (es) Derivados de piridazina
ATE554085T1 (de) Neue inhibitoren von glutaminylcyclase
BRPI0719393B8 (pt) composição farmacêutica
MY138941A (en) Aryl-pyridine derivatives
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
EA201270540A1 (ru) Макроциклические ингибиторы интегразы
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
AR056337A1 (es) Derivados de alquil-, alquenil- y alquinilcarbamatos, su preparacion y su aplicacion en terapeutica
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
UY29844A1 (es) Formulación en aerosol para la inhalación de beta-agonistas
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
NO20090270L (no) Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister

Legal Events

Date Code Title Description
8364 No opposition during term of opposition